REGISTER
Matteo Carlino on INTerpath-001 and Individualized Neoantigen Therapy in Melanoma
At ESMO 2026, Matteo Carlino discusses INTerpath-001, a phase 3 study of intismeran autogene plus pembrolizumab after melanoma resection. He reviews recurrence outcomes and tolerability, and explains how tumor sequencing, neoantigen selection, and individualized manufacturing fit into postoperative care.

0
0
Loading